Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
BeOne Medicines
MOMA Therapeutics
Eli Lilly and Company
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Nammi Therapeutics Inc
National Cancer Institute (NCI)
Conjupro Biotherapeutics, Inc.
Conjupro Biotherapeutics, Inc.
GlaxoSmithKline
SystImmune Inc.
Orano Med LLC
Atavistik Bio, Inc
Alterome Therapeutics, Inc.
ViroMissile, Inc.
Myeloid Therapeutics
Tizona Therapeutics, Inc
Leiden University Medical Center
Clasp Therapeutics, Inc.
Angiex, Inc.
Poseida Therapeutics, Inc.
IDEAYA Biosciences
Baylor College of Medicine
MacroGenics
Avacta Life Sciences Ltd
Oscotec Inc.
M.D. Anderson Cancer Center
OncoNano Medicine, Inc.
AstraZeneca
Nuvation Bio Inc.
National Cancer Institute (NCI)
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
Exelixis
Senhwa Biosciences, Inc.
Jonsson Comprehensive Cancer Center
Novita Pharmaceuticals, Inc.
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
University of Virginia
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
German Cancer Research Center
Columbia University
Black Diamond Therapeutics, Inc.
Tomsk National Research Medical Center of the Russian Academy of Sciences
Orion Biotechnology Polska Sp. z o.o.
National Cancer Institute (NCI)
Daiichi Sankyo
Carisma Therapeutics Inc